BPMC Overview
Upcoming Projects (BPMC)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BPMC)
-
Discussing current commercial use of Ayvakit and the ongoing SUMMIT trial evaluating bezuclastinib in iSM (indolent systemic mastocytosis)
Tickers: COGT, BPMC
Executed On: Jun 12, 2025 at 12:00 PM EDT -
Discussing the recent part 1b results from the SUMMIT trial evaluating bezuclastinib in iSM (indolent Systemic Mastocytosis) presented at AAAAI
Tickers: COGT, BPMC
Executed On: Mar 28, 2024 at 09:00 AM EDT -
Discussing the ISM treatment landscape and the potential of AYVAKIT (avapritinib) with current prescribers
Ticker: BPMC
Executed On: Jan 24, 2024 at 04:15 PM EST -
A Second Opinion: Discussing the ASH 2023 data from Cogent's bezuclastinib (SUMMIT STUDY) and BluePrint's elenestinib (HARBOR study) for treating indolent systemic mastocytosis
Tickers: COGT, BPMC
Executed On: Dec 22, 2023 at 12:00 PM EST -
Discussing the ASH 2023 data from Cogent's bezuclastinib (SUMMIT STUDY) and BluePrint's elenestinib (HARBOR study) for treating indolent systemic mastocytosis
Tickers: COGT, BPMC
Executed On: Dec 20, 2023 at 01:00 PM EST -
Discussing C-Kit targeting for CSU (chronic spontaneous urticaria), PN (prurigo nodularis, EOE (eosinophilic esophagitis), aSM (advanced systemic mastocytosis), and iSM (indolent systemic mastocytosis)
Tickers: CLDX, JSPR, BPMC, COGT
Executed On: Sep 12, 2023 at 10:30 AM EDT -
A Third View: Examining the recent data from the PIONEER Trial of Blueprint's AYVAKIT (avapritinib) in treating patients with Indolent Systemic Mastocytosis
Ticker: BPMC
Executed On: Apr 04, 2023 at 11:30 AM EDT -
A Second View: Examining the recent data from the PIONEER Trial of Blueprint's AYVAKIT (avapritinib) in treating patients with Indolent Systemic Mastocytosis
Ticker: BPMC
Executed On: Mar 22, 2023 at 10:30 AM EDT -
Examining the recent data from the PIONEER Trial of Blueprint's AYVAKIT (avapritinib) in treating patients with Indolent Systemic Mastocytosis
Ticker: BPMC
Executed On: Mar 10, 2023 at 02:00 PM EST -
A Second View: Digging into the potential of AYVAKIT (avapritinib) as part of treatment in patients with non advanced systemic mastocytosis
Ticker: BPMC
Executed On: Aug 23, 2022 at 12:00 PM EDT -
Digging into the potential of AYVAKIT (avapritinib) as part of treatment in patients with non advanced systemic mastocytosis
Ticker: BPMC
Executed On: Aug 23, 2022 at 10:00 AM EDT -
Checking on the systemic mastocytosis landscape with a focus on the potential of Ayvakit (avapritinib), BLU-263, and Bezuclastinib (CGT9486/ PLX9486)
Tickers: BPMC, COGT
Executed On: Mar 31, 2022 at 12:00 PM EDT
Expired Projects (BPMC)
-
Discussing Blueprint Medicines’ FDA Approval of AYVAKIT for treating systemic mastocytosis
Ticker: BPMC
Execute By: Jun 30, 2023 -
A 3rd Look - Understanding Disease Management in Systemic Mastocytosis - A Look at Pipeline Products from Blueprint & Deciphera
Tickers: BPMC, DCPH
Execute By: Sep 20, 2018
Upcoming & Overdue Catalysts (BPMC)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BPMC)
Strategic Initiatives (BPMC)
-
Blueprint Medicines (BPMC) to acquire Lengo Therapeutics for $250M in cash
Ticker: BPMC
Announcement Date: Nov 29, 2021
